Third C-Suite Buy in 48 Hours. Pattern Emerging.
This is the third Summit Therapeutics executive to step in with serious money this week. Co-CEO Robert Duggan just bought $1.46 million at $14.60, following yesterday's $1.46 million buy from the other Co-CEO and $722K from the COO. The technicals are ugly with selling pressure across all timeframes, but when three C-suite executives risk this much capital in two days, they see something the market doesn't. RSI at 36 suggests oversold conditions, and at $14.60 you're buying right alongside the insider cluster.
The Filing
| Ticker | SMMT |
| Company | Summit Therapeutics Inc. |
| Insider | Robert Duggan, Co-Chief Executive Officer |
| Buy amount | $1.5M |
| Filing date | June 4, 2026 |
| Conviction | Favorable · 68/100 |
| Setup type | Oversold Bounce |
Ultimate members received this analysis in real time.